|
|
|
|
|
Highlights from the 2023 Society of Urologic Oncology 24th Annual Meeting
|
|
|
|
|
| Androgen Receptor Agonist versus Antagonist: Cardiac Morbidity
|
| Alicia Morgans, MD, MPH
|
| Alicia Morgans discusses the cardiac morbidity associated with androgen receptor (AR) agonists compared to AR antagonists in the context of androgen deprivation therapy for prostate cancer. Dr. Morgans emphasized the importance of considering cardiovascular health when choosing ADT and highlighted potential differences in cardiovascular risk between GnRH agonists and antagonists.
|
|
|
|
|
|
| Active Surveillance for Prostate Cancer: The 5 Ws and 1 H Framework
|
| Simpa Salami, MD, MPH
|
| Simpa Salami presents a comprehensive overview of active surveillance for prostate cancer using the '5 Ws and 1 H' framework. Dr. Salami discussed the criteria for selecting candidates, recommended testing intervals, available tools (such as PSA, biopsies, MRI, and biomarkers), and special considerations for specific patient groups.
|
|
|
|
|
|
| Current Advances in Robotic Prostatectomy
|
| Jim Hu, MD, MPH
|
| Jim Hu discusses recent advances in robotic prostatectomy. Key points included the evolution of post-operative outcomes, such as shortened hospital stays and reduced adverse events. Dr. Hu also highlights techniques like Retzius-sparing approaches and the Pelvic fascia-spAring radical prostatectomy TrIAL (PARTIAL) to improve functional outcomes.
|
|
|
|
|
|
|
|
|
|
|
| Artificial Intelligence for Diagnosis and Grading of Prostate Cancer
|
| Peter Humphrey, MD, Ph.D.
|
| Peter Humphrey presents a comprehensive overview of the novel applications of artificial intelligence tools in urologic pathology. Dr. Humphrey emphasizes the promising performance of AI systems in grading, potentially surpassing general pathologists. Despite current challenges, the future integration of AI into pathology workflows is foreseen, with the transition to direct-to-digital pathology slides and 3D imaging.
|
|
|
|
|
|
| Development of Prostate Cancer in Transgender Women
|
| Stephen Freedland, MD
|
| Stephen Freedland presents the development of prostate cancer in transgender women, an area of ongoing research. Key objectives of the presentation included reviewing contemporary literature on prostate cancer in transgender women, discussing the known aspects of PSA screening in this population, and proposing tips for providing patient-centered care for transgender patients.
|
|
|
|
|
|
| Bone Support Throughout the Prostate Cancer Journey |
| Philip Saylor, MD
|
| Philip Saylor discusses the use of bone-supportive agents throughout a patient's prostate cancer journey. Dr. Saylor provides insights into the use of bone-supportive agents across different stages of prostate cancer, emphasizing their role in managing bone health and reducing the risk of SREs.
|
|
|
|
|
|
| Ongoing Clinical Trials for Metastatic Castration-Sensitive Prostate Cancer
|
| Evan Yu, MD
|
| Evan Yu provided an overview of ongoing clinical trials in metastatic castration-sensitive prostate cancer. He highlighted recent advances, emphasizing the shift from doublet therapy with docetaxel + hormone therapy to triplet therapy with androgen deprivation therapy plus androgen receptor pathway inhibitors.
|
|
|
|
|
|
| Serial Next-Generation Sequencing and the Role of PARP Inhibitor Therapy in 2024
|
| Alan Bryce, MD
|
| Alan Bryce presents the use of serial next-generation sequencing (NGS) in castrate-resistant prostate cancer. Dr. Bryce discussed the evolving mutational landscape in prostate cancer, the discordance between plasma and tissue testing, and the complexities of managing toxicities associated with PARP inhibitor therapy.
|
|
|
|
|
|
|
